Ravishankar Vadali

Attention Life Science Professionals! 🔥 ANOTHER HOT TOPIC ALERT! 🧪🔬 Some More Good News in the Life Sciences! Check out the summary below regarding the 3,000 jobs created in Boston area in 2024. Share your thoughts in the comments! And if you are looking for folks, please let us know! hashtag #lifesciences #biotech #pharma #medicaldevice #diagnostics #hiring2024 #boston The Richmond Group USA

6

🗞 Breaking news 🤩 Genezen acquire uniQure's commercial GT manufacturing ops in Lexington!! This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Check out full article below👇 #CDMO #Genezen #GeneTherapy

18

𝐑𝐄𝐆𝐔𝐋𝐀𝐓𝐎𝐑𝐘 𝐑𝐎𝐔𝐍𝐃𝐔𝐏 ⚛️ The FDA has released new draft guidance recommending best practices for multi-regional clinical trials (MRCTs) in oncology. Sponsors are encouraged to ensure that the outcomes of global oncology clinical development programs are understandable for US patients in support of marketing applications. 🌐 The FDA's final guidance on decentralized clinical trials (DCTs) clarifies several concerns raised by clinical experts and industry stakeholders regarding the earlier draft. This includes detailed requirements for maintaining a task log for healthcare providers, guidelines for physical inspections, and addressing challenges related to data variability in DCTs. 🤖 As the use of artificial intelligence (AI) tools, particularly generative AI, expands, experts remind regulatory professionals to prioritize the human aspect. Although these tools offer significant benefits, they necessitate human oversight and interpretation to be fully effective. During the opening plenary session, experts discussed how AI can be utilized across various sectors, the potential of this technology, and the hurdles in achieving its full benefits. Panelists included Ryan Kurtzman from the City of Long Beach, Bradley Thompson of Epstein Becker Green, Michelle Jump from MedSec, and Jay Mashburn from Recursion Pharmaceuticals, with moderation by Megha Iyer of Thermo Fisher Scientific. 🧬 As biosimilars gain market presence, they are generating competition with original products. However, patient adoption of biosimilars varies based on demographics, location, care setting, prescriber specialties, and types of insurance, according to two recent studies in Health Affairs. 🌐 The FDA has observed a rise in complete response letters (CRLs) issued to sponsors of biologics license applications (BLAs) over the last decade, with facility deficiencies being the most common reason cited, according to Leslie Rivera Rosado, a supervisory interdisciplinary scientist at the agency's Center for Drug Evaluation and Research (CDER). #Pharmaceuticals #Biotechnology #LifeSciences #PharmaNews #Biotech #HealthcareInnovation #DrugDevelopment #ClinicalResearch #Biopharma #PharmaTech #MedicalResearch #Healthcare #BioPharmaceuticals #PharmaIndustry #BiotechIndustry #PharmaCareers #MedicalInnovation #NewDrugs #Genomics #BiotechNews

14

80% of Massachusetts Bioscience graduates are being pulled into careers outside of Life Sciences! This years headlines have been dominated by layoffs, but whilst the industry continues to recover and companies begin to hire again, the demand for talent will only increase. MassBioEd CEO, Sunny Schwartz claims “Some of them may be thinking that the only option is med school". As a Biochemistry graduate who went from an MSc, straight into a career of Life Science recruitment, with the main reason being I had no idea what else was out there! Nine years on, I can safely say I made a great choice, but had I known what else was out there, maybe I would've taken a different path? How can we go about increasing the awareness of the fantastic careers that Biotech can offer for our next generation of graduates? #Biotech #lifesciences #MassBioEd

43

2 Comments

🌟 Exciting News from BeiGene! 🌟 BeiGene unveiled its flagship biologics manufacturing and R&D center in Hopewell, New Jersey! This new 42-acre campus signifies a major step forward in innovation and partnerships in the biologics space. 🏢🔬 Key Highlights: -State-of-the-Art Facility: The site features 400,000 sq. ft. of commercial production space, with a capacity for 2 million vials per year and room for future expansion. 🌐 -Strategic Location: Originally owned by Bristol Myers Squibb, the campus provides a robust infrastructure for growth. 📍 -Collaboration Potential: CEO John Oyler is optimistic about new partnerships, emphasizing BeiGene's capabilities in co-development and co-commercialization. 🤝 Supporting Tevimbra: The new site will play a pivotal role in the launch of BeiGene's first biologic product in the U.S., the PD-1 inhibitor Tevimbra. This ensures timely FDA inspections and reliable production. 🚀 Global Reach: BeiGene continues to expand its footprint, combining deep roots in China with a strong presence in the U.S. and beyond. 🌍 With the opening of this advanced facility, BeiGene is poised for exciting new collaborations and breakthroughs in biologics. Stay tuned for more updates! #Biotech #Innovation #Biologics #Pharma #Partnerships #Healthcare #ResearchAndDevelopment #BeiGene #GlobalExpansion #Tevimbra #HopewellNJ 📸: BeiGene CEO John Oyler and NJ Governor Phil Murphy celebrating the opening of the Hopewell site.

1

1 Comment

The latest U.S. Biotechnology Instruments Market report unveils remarkable growth and new opportunities. Here are 10 essential takeaways for every biotech professional: 1️⃣ Market Growth Projections: The market is set to surge from USD 36.16 billion in 2024 to an impressive USD 49.11 billion by 2033, with a CAGR of 3.46%. 2️⃣ Dominance of Analytical Instruments: Analytical instruments, holding a 65.9% market share in 2023, play a vital role in biotechnological applications, from research to quality control. 3️⃣ Rapid Growth in Cell Culture Instruments: The cell culture instruments segment is poised for the fastest growth through 2033, driven by advancements in biopharmaceuticals, regenerative medicine, and personalized healthcare. 4️⃣ Pharmaceutical & Biotech Companies Lead in End-Use: Dominating the end-use segment with a 40.11% market share in 2023, these companies showcase the industry's dedication to drug discovery and genetic engineering. 5️⃣ Rising Investment in Precision Medicine: With expanding applications, precision medicine presents substantial opportunities, boosting demand for biotechnology instruments crucial for genomic sequencing and biomarker analysis. 6️⃣ Regional Innovation Hubs: California and Massachusetts remain strongholds of biotech innovation, with emerging clusters in Texas and North Carolina contributing significantly to industry growth. 7️⃣ Addressing Regulatory Challenges: Navigating regulatory complexities, especially around gene editing and stem cell research, is crucial for sustaining innovation and market growth. 8️⃣ Global Market Size Estimates: The global biotech instruments market is projected to grow from USD 89.85 billion in 2023 to USD 132.36 billion by 2033, at a CAGR of 3.95%. 9️⃣ Recent Product Innovations: 2024 saw notable advancements, including LICORbio's Odyssey® F biomolecular imaging systems and Waters Corporation’s Alliance iS Bio HPLC System, enhancing productivity and research capabilities. 🔟 Impact of Biopharmaceutical R&D: The expansion of biopharmaceutical R&D, focusing on biologic drugs like monoclonal antibodies and cell therapies, is driving increased demand for sophisticated biotechnology instruments. For those looking to stay ahead, these insights provide a roadmap to understanding market dynamics and seizing growth opportunities. Dive into the full report for an in-depth analysis. Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @ https://lnkd.in/dGry4wGJ #Biotech #MarketInsights #Innovation #PrecisionMedicine #Genomics #Biopharmaceuticals #BiotechInvestments #RegulatoryAffairs #BiotechResearch #MarketGrowth Let's continue to elevate the biotech industry together! 🚀

2

Quick read on the pivotal shift in the biopharmaceutical industry. It really highlights that manufacturing capabilities are now at the forefront of investment discussions, which is now overshadowing traditional focuses like new drug indications. As companies demonstrate, through hands-on investor engagement, understanding and scaling manufacturing processes has become crucial for attracting funding and ensuring successful drug development in a rapidly evolving market. #GxP #Quality #funding #biotech #manufacturing

3

🌟 Standing Out in a Challenging Market 🌟 In an era where many companies are tightening belts post-budget, we at Sarto Thomas are taking a different path. 💼✨ While some of our competitors scale back, we’re investing more in what really drives us: our people. That's why we've enhanced benefits, a re-energised our commission structure, and the resources needed to help our team thrive. 🎯💰 ·        15% commission with ZERO THRESHOLD ·        EOQ and Annual performance bonuses related to sales target ·        4 & 5 figure bonuses for achieving personal sales milestones ·        25 days annual leave ·        7 Company funded social events ·        Clear promotion criteria, with personal development plans ·        Grade specific travel allowance It's not just about weathering the storm; it’s about setting ourselves up for the future—and bringing the best talent along with us. If you want to be part of a recruitment team that sees the big picture and invests in its people, let's talk. Below are are current vacancies, check them out. 👉 Link to Trainee Recruitment Consultant Role https://lnkd.in/eVu7vqs8 👉 Link to Recruitment Consultant Role https://lnkd.in/eeqgZaia #SartoThomas #Recruitment #WeInvestInPeople #LeadingTheWay #recruitmentjobs Sarto Thomas Ltd Lewis Lewis Becky Jon

16

4 Comments

The biopharma market appears to be stabilizing amid broader economic uncertainties, suggesting that companies may need to adapt to a new normal characterized by cautious investment and innovation strategies. This shift could foster a more resilient industry, but it also raises concerns about the long-term impact on research and development funding. #GxP #Quality #biotech #funding #lifesciences

4

Enveda, a biotechnology company leveraging AI to develop new medicines, has successfully closed a $130 million Series C funding round, bringing its total funding to $360 million. This capital will support the advancement of its pipeline of 10 development candidates and is expected to generate multiple clinical catalysts in 2025 and 2026. #Funding #GxP #Quality #Biotech

8

💥 SUPER MSL: The Quest to Become the TOP MSL on Your Team💥 Don't miss this weeks MSL Talk podcast with Daniel Snyder, Ph.D., Senior Medical Affairs & HEOR Leader who discusses the differentiators for MSLs that will make you stand out and become the top MSL on your team. Learn more about….   👉 The qualities and differentiators of a “Super MSL” 👉 The skills and attributes that make MSLs stand out relative to their peers 👉 What common mistakes do MSLs need to avoid to 👉 What MSL Team leader should do to encourage and entice ideal MSL skills The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #MSLtalk #careers  

32

3 Comments

💥 SUPER MSL: The Quest to Become the TOP MSL on Your Team💥 Don't miss this weeks MSL Talk podcast with Daniel Snyder, Ph.D., Senior Medical Affairs & HEOR Leader who discusses the differentiators for MSLs that will make you stand out and become the top MSL on your team. Learn more about…. 👉 The qualities and differentiators of a “Super MSL” 👉 The skills and attributes that make MSLs stand out relative to their peers 👉 What common mistakes do MSLs need to avoid to 👉 What MSL Team leader should do to encourage and entice ideal MSL skills The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLtalk #careers

27

1 Comment

A big thank you to HBA NY Tri-State region's Central NJ chapter and Sanofi for hosting an exceptional event on market access in the pharmaceutical industry. The panel did an outstanding job educating attendees on the crucial role market access plays within pharma organizations. 📝 Key takeaways⭐️: 📓Commit to learning: If you're considering market access as part of your career path, don't just dip your toes in. Dedicate 2-3 or more years or more to truly understand the field's complexities. ❓Cultivate curiosity: Success in market access hinges on asking the right questions. Develop a mindset of continuous inquiry to excel in this role. 🏃‍♂️‍➡️Stay adaptable: The market access landscape evolves rapidly. Be prepared to keep learning and adjusting your strategies as the field changes. This event reinforced the importance of market access in shaping the future of pharmaceutical companies and patient care. Negelle Morris Nazanin Mehin Olivier Bogillot Garrett Ingram Lalitha P. Chandrashekhar #MarketAccess #Pharma #ProfessionalDevelopment #HBACentralNJ #Sanofi

111

4 Comments

The Q3 Job Market Report from BioSpace just dropped, and you definitely want to check it out! The life sciences job market is going through some big changes, and keeping up with the latest info is super important for navigating it all. According to the new BioSpace data, there are some challenges but also plenty of opportunities coming up! 🔍 Key Insights from BioSpace's Q3 2024 Report: 1. Decrease in Job Postings:   - There were 21,548 jobs live on BioSpace in Q3 2024.   - This is a 12% decrease from 24,503 jobs in Q3 2023. 2. Increase in Job Competition:   - The job response rate (percentage of people applying after viewing) jumped from 9.8% to 14.8%, a 51% increase year-over-year.   - Notably, from July to September 2024, the response rate surged from 14.5% to 18.4%, a 26.9% increase. 3. Top States for Job Openings:   - California: 3,769 jobs   - Massachusetts: 3,110 jobs   - New Jersey: 2,513 jobs   - Illinois: 2,452 jobs   - New York: 1,717 jobs 4. Impact of Layoffs:   - In Q3 2024, there were 54 rounds of layoffs in biotech and pharma, affecting at least 3,700 employees.   Significant layoffs included:    - FibroGen, Inc.: Let go of 75% of its U.S.-based workforce (~356 people).    - GRAIL: Laid off about 350 employees.    - BioMarin Pharmaceutical Inc.: Cut 225 positions globally.    - Johnson & Johnson & Bayer: Combined layoffs of 288 employees in New Jersey. 💡 What This Means for You: - Increased Competition: With fewer job postings and more professionals in the market, it's crucial to differentiate yourself. - Strategic Job Hunting: According to Carina Clingman, PhD, CEO of Recruitomics Consulting, fall is prime time for job hunting in biotech. Companies aim to fill positions before the budget cycle ends around Thanksgiving. 📈 Emerging Opportunities:  - Johnson & Johnson is investing $2 billion in a new biologics manufacturing plant in Wilson, North Carolina, expected to create 420 new full-time, highly skilled jobs. Construction begins in the first half of 2024.  - Eli Lilly and Company is committing $4.5 billion to build a facility in Lebanon, Indiana, housing research and manufacturing. Set to open in late 2027, it will employ about 400 new engineers, scientists, lab technicians, and operations personnel.  - MassBio's 5-Year Plan: Aiming to create hundreds of new biopharma and life sciences positions in Massachusetts by 2030, focusing on supporting early-stage biotech growth. 🚀 Tips to Stay Ahead: - Update Your Skills: Leverage this time to enhance your expertise and stay competitive. - Network: Engage with industry peers and attend virtual or in-person events. - Stay Informed: Keep an eye on emerging biotech hubs and companies expanding their workforce. - Be Proactive: Tailor your applications and highlight how you can add value in this dynamic environment. Share your experiences or tips below. #Biotech #Pharma #JobMarket #CareerGrowth #LifeSciences

4

The article discusses Jupiter Bioventures recent $70 million fund aimed at supporting cancer biotechs, it shows a growing trend of investment in cancer therapies. This funding reflects a strong commitment to advancing cancer research and patient outcomes. #GxP #funding #oncology #Quality

6

🚀 Biopharma Market Expansion: Key Takeaways As biopharma companies explore new markets, it's crucial for leaders to tailor their approach to the unique nuances of each market. Here are some critical insights: 1️⃣ Revenue Potential: By 2028, markets outside the US are projected to generate US$120 billion in revenue, presenting substantial growth opportunities. 2️⃣ 2023 Revenues: Non-US markets accounted for 56% of global biopharma revenue in 2023, up from 52% in 2020. This trend underscores the growing importance of international markets. 3️⃣ Patent Cliff: The industry faces a $200 billion revenue risk from expiring patents by 2030, pushing companies to diversify globally. 4️⃣ Global Market Size: The global biopharma market was valued at US$1.4 trillion in 2023, highlighting the vast scale and potential of the industry. 5️⃣ Strategy Models: Large biopharmas (≥ US$20 billion annual revenue) prefer direct presence in significant markets, while smaller firms (≤ US$5 billion) often opt for distributor partnerships in complex regions. 6️⃣ Operational Challenges: Tailored entry strategies are essential due to varying regulatory, reimbursement, and tax considerations across different countries. 7️⃣ Strategic Focus: Companies should prioritize specific countries, develop tailored entry models, establish robust launch sequences, and build cross-functional capabilities to mitigate risks. Planning and executing a well-thought-out international expansion strategy can help biopharma companies maximize revenue potential and patient reach worldwide. 🌍💉 #Biopharma #MarketExpansion #GlobalGrowth #Biotech #Pharmaceuticals #Strategy #RevenueGrowth P.S. How is your company planning to navigate these market opportunities in 2024? Share your insights below.

3

💥 Leveraging Real-World Evidence (RWE) in MSL Activities 💥 Don't miss this weeks MSL Talk Podcast with Elizabeth Pash, PhD, MS, RDN, Medical Affairs Executive Leader who shares insights on how to leverage real-world evidence (RWE) in MSL activities. This episode is sponsored by MSL Mastery, helping Medical Science Liaisons and aspiring MSLs to excel in their careers and lives through courses, coaching, and community. For more details, please visit MSLmastery (dot) com. In this episode, Beth discusses… 👉 What is Real World Evidence and how it is different from Clinical Trial Data 👉 How MSLs can effectively incorporate RWE into their discussions with healthcare professionals and key opinion leaders (KOLs) 👉 Challenges MSLs typically face when presenting RWE to stakeholders, and how can they overcome them 👉 Ways RWE can be used to enhance the strategic value of MSL activities 👉 Key skills MSLs need to develop in order to effectively understand and communicate RWE to diverse audiences The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #realworldevidence #careers

19

𝗗𝗮𝗶𝗹𝘆 𝗡𝗲𝘂𝗿𝗼-𝗯𝗶𝘁𝗲𝘀 🧠: 💵𝘾𝙤𝙣𝙜𝙧𝙖𝙩𝙪𝙡𝙖𝙩𝙞𝙤𝙣𝙨 to CereVasc who secures $70 million series B financing, following FDA approval of STRIDE study 𝗦𝗼, 𝘄𝗵𝗮𝘁 𝗮𝗿𝗲 𝘁𝗵𝗲𝘆 𝗴𝗼𝗶𝗻𝗴 𝘁𝗼 𝘂𝘀𝗲 𝘁𝗵𝗶𝘀 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝗳𝗼𝗿? 🧑‍💻Support the clinical and regulatory development of the company’s novel eShunt system ⚕️Fund their upcoming STRIDE pivotal study involving patients with normal-pressure hydrocephalus. 🤔𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝘁𝗵𝗲𝗶𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝗱𝗼? Their eShunt System is a minimally invasive approach to treating hydrocephalus. The System comprises an endovascularly implantable CSF shunt and associated delivery component. This is designed to avoid the need for: ⭐Invasive surgery ⭐General anesthesia ⭐Extended hospitalization ⭐Post-procedure pain management. #hydrocephalus #brainhealth #minimallyinvasive #patientoutcomes #neurovascular https://lnkd.in/e-R5wkkQ https://lnkd.in/enfjKs_E

10

Eli Lilly and Company Soars to New Heights on Stellar Drug Performance 🚀 💰 📈 Eli Lilly delivered a financial masterclass with its phenomenal Q2 sales topping $11.3 billion! This surge is largely thanks to the diabetes and obesity blockbusters Mounjaro and Zepbound, sending Lilly's stock skyrocketing 7% 📈. The company even hiked its 2024 guidance, projecting a whopping $45.4-46.6 billion revenue range! 🏆 What's driving this success? - Mounjaro and Zepbound: These GLP-1 receptor agonists are changing the game in diabetes and obesity treatment, offering efficient blood sugar control and significant weight loss 📉. Mounjaro alone generated a staggering $3.1 billion in Q2 sales! - Streamlined Manufacturing: Lilly has cleverly overcome Zepbound's initial supply chain hurdles, making all vial sizes available and ensuring patients have access to this crucial medication. 📈 Investors Applaud Wall Street is clearly impressed, with analysts revising their outlook on Lilly's potential. This positive sentiment is a clear vote of confidence for the company's future. 💡 What's Next for Lilly? The company is pushing R&D boundaries with an oral GLP-1 and dual GLP-1/GIP therapy in the pipeline. Their dedication to innovation paves the way for further breakthroughs in diabetes, obesity, and Alzheimer's treatment. 🤔 Is Eli Lilly the Next Pharma Powerhouse? With financials booming and revolutionary drugs in their arsenal, Lilly is undoubtedly a force to be reckoned with. Their commitment to growth and improving patient outcomes points to a bright future. What are your thoughts on Lilly's trajectory? Share your insights in the comments! #EliLilly #Mounjaro #Zepbound #FinancialResults #PharmaInnovation #Diabetes #Obesity #RD #Growth

1